{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:54:51Z","timestamp":1793660091368,"version":"4.5.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>X-linked hypophosphatemia (XLH) is a rare, genetic, progressive, lifelong disorder caused by pathogenic variants in the <jats:italic>phosphate-regulating endopeptidase homolog, X-linked (PHEX)<\/jats:italic> gene, resulting in excess fibroblast growth factor 23 (FGF23) and consequent renal phosphate wasting. Chronic hypophosphatemia leads to deficits of the musculoskeletal system affecting bone, muscle, joint, and dental health. XLH treatments include oral phosphate and active vitamin D\u2014which are associated with a burdensome dosing regimen, gastrointestinal disturbances, hyperparathyroidism, and nephrocalcinosis\u2014or burosumab, a fully human anti-FGF23 antibody. Randomized clinical trials (RCTs) demonstrated burosumab to be well tolerated and efficacious in improving serum phosphate, rickets, bone turnover, and patient-reported outcomes. However, there are limited data on the natural history of XLH or real-world comparisons of the safety, effectiveness, and long-term outcomes of XLH treatments. Advancing Patient Evidence in XLH (APEX) is a global data unification project aiming to describe the burden and lifelong progression of XLH, collect real-world data on treatment effectiveness and safety, and investigate regional differences in treatment outcomes. Participants from three observational, noninterventional, retrospective and prospective, multicenter, longitudinal (10-year) studies of patients with XLH will be included: XLH Disease Monitoring Program (NCT03651505), International XLH Registry (NCT03193476), and SUNFLOWER (NCT03745521). Data collected in the Americas, Europe, Israel, Japan, and South Korea will be processed to unify identical and similar data elements. Data unification will be an iterative process with a clinical and programming review, ensuring validity and accuracy. In this observational study, unified data involving approximately 2000 pediatric and adult participants with XLH will be analyzed to address research questions in an exploratory manner. Long-term observational studies and patient registries provide opportunities to generate real-world data and address knowledge gaps in rare diseases. APEX aims to improve clinical decision-making and practice by bridging evidence gaps that cannot be addressed by RCTs or regional registries.<\/jats:p>","DOI":"10.3389\/fendo.2025.1471127","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:10:52Z","timestamp":1743999052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program"],"prefix":"10.3389","volume":"16","author":[{"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith P.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-020-01434-4","article-title":"The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study","volume":"15","author":"Padidela","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: A United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1529-z","article-title":"Clinical practice: diagnostic approach to the rachitic child","volume":"170","author":"Rajah","year":"2011","journal-title":"Eur J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.11.8923863","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10728","article-title":"Craniosynostosis in patients with X-linked hypophosphatemia: A review","volume":"7","author":"Munns","year":"2023","journal-title":"JBMR Plus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course","volume":"5","author":"Cheung","year":"2021","journal-title":"J Endocr Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.11.019","article-title":"Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia","volume":"95","author":"Boukpessi","year":"2017","journal-title":"Bone"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0022034517728497","article-title":"Defective mineralization in X-linked hypophosphatemia dental pulp cell cultures","volume":"97","author":"Coyac","year":"2018","journal-title":"J Dent Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/genes13081356","article-title":"PHEX(L222P) mutation increases phex expression in a new ENU mouse model for XLH disease","volume":"13","author":"El Hakam","year":"2022","journal-title":"Genes (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s004310050962","article-title":"Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets","volume":"157","author":"Kruse","year":"1998","journal-title":"Eur J Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-2046-z","article-title":"Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment","volume":"27","author":"Quinlan","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11657-021-00879-9","article-title":"Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries","volume":"16","author":"Al Juraibah","year":"2021","journal-title":"Arch Osteoporos"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"key":"B24","unstructured":"CRYSVITA. Summary of Product Characteristics"},{"key":"B25","volume-title":"Crysvita Full Prescribing Information","year":""},{"key":"B26","unstructured":"Kyowa Kirin Announces Approval of Crysvita\u00ae (burosumab) for the Treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia in Japan"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211001150","article-title":"Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy","volume":"12","author":"Brener","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00381-8","article-title":"New developments in the treatment of X-linked hypophosphataemia: implications for clinical management","volume":"22","author":"Saraff","year":"2020","journal-title":"Paediatr Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","article-title":"Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenicky","year":"2023","journal-title":"RMD Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13023-022-02562-9","article-title":"Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone","volume":"17","author":"Ertl","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae398","article-title":"Improved oral health in adults with X-linked hypophosphatemia treated with burosumab","author":"Herv\u00e9","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05190-y","article-title":"Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study","volume":"182","author":"Levy-Shraga","year":"2023","journal-title":"Eur J Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00048","article-title":"Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia","volume":"8","author":"Martin Ramos","year":"2020","journal-title":"Front Pediatr"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae079","article-title":"Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study","volume":"8","author":"Michigami","year":"2024","journal-title":"JBMR Plus"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.866170","article-title":"Persistent lower limb deformities despite amelioration of rickets in X-linked hypophosphatemia (XLH) - A prospective observational study","volume":"13","author":"Mindler","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05484-7","article-title":"Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets","volume":"37","author":"Paloian","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116791","article-title":"Prevalence and characteristics of paediatric X-linked hypophosphataemia in Australia and New Zealand: Results from the Australian and the New Zealand Paediatric Surveillance Units survey","volume":"173","author":"Sandy","year":"2023","journal-title":"Bone"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/bpb.0000000000001054","article-title":"Changes of the lower limb deformity in children with FGF23-related hypophosphatemic rickets treated with Burosumab: a single-center prospective study","volume":"33","author":"Sawamura","year":"2024","journal-title":"J Pediatr Orthop B"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2387","article-title":"Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts","volume":"12","author":"Vaisbich","year":"2024","journal-title":"Mol Genet Genomic Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2022-324962","article-title":"Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels","volume":"108","author":"Walker","year":"2023","journal-title":"Arch Dis Child"},{"key":"B50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13023-021-01872-8","article-title":"The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results","volume":"16","author":"Bassanese","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B51","unstructured":"X-linked Hypophosphatemia Disease Monitoring Program"},{"key":"B52","unstructured":"Registry for Patients With X-Linked Hypophosphatemia (International XLH Registry)"},{"key":"B53","unstructured":"Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets\/\u200bOsteomalacia in Collaboration With Asian Partners (SUNFLOWER)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036367","article-title":"Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study","volume":"10","author":"Kubota","year":"2020","journal-title":"BMJ Open"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100395","DOI":"10.1016\/j.xkme.2021.10.008","article-title":"Potential surrogate outcomes for kidney failure in advanced CKD: evaluation of power and predictive ability in CKDopps","volume":"4","author":"Zee","year":"2022","journal-title":"Kidney Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-81","article-title":"The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry","volume":"9","author":"Viviani","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2022-0365","article-title":"Rare PHEX intron variant causes complete and severe phenotype in a family with hypophosphatemic rickets: a case report","volume":"36","author":"Aiello","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/genes14010080","article-title":"The variant p.Ala84Pro is causative of X-linked hypophosphatemic rickets: possible relationship with burosumab swinging response in adults","volume":"14","author":"Zagari","year":"2022","journal-title":"Genes (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","article-title":"Health care transition from pediatric- to adult-focused care in X-linked hypophosphatemia: expert consensus","volume":"107","author":"Dahir","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1471127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:11:10Z","timestamp":1743999070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1471127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":60,"alternative-id":["10.3389\/fendo.2025.1471127"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1471127","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1471127"}}